Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | DHPS | P49366 | 8/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | CCR4 | P51679 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5512885 | 0.77 | STING1 (0.46) | AHR | |
| SCHEMBL2713353 | 0.75 | MAPK1 (0.56) | MAPK1HTR6DHPSAHREGFR | |
| SCHEMBL349436 | 0.74 | MAPK1 (0.51) | MAPK1HTR6DHPSAHREGFR | |
| SCHEMBL28743516 | 0.74 | MAPK1 (0.51) | MAPK1HTR6DHPSAHREGFR | |
| Hydrochloric Acid SCHEMBL27532366 | 0.73 | MAPK1 (0.54) | MAPK1HTR6DHPSAHREGFR | |
| SCHEMBL28228531 | 0.73 | MAPK1 (0.50) | MAPK1HTR6DHPSAHREGFR | |
| SCHEMBL4025098 | 0.73 | MAPK1 (0.63) | MAPK1HTR6DHPSAHRTRPV1 | |
| SCHEMBL29901215 | 0.73 | MAPK1 (0.63) | MAPK1HTR6DHPSAHRTRPV1 | |
| SCHEMBL257380 | 0.71 | MAPK1 (0.71) | MAPK1HTR6DHPSAHRTRPV1 | |
| SCHEMBL30955295 | 0.71 | HTR6 (0.60) | MAPK1HTR6DHPSAHRCCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2275433-B1 | METASTIN DERIVATIVE AND USE THEREOF | UNIV KYOTO (JP) | 2017-06-07 | — | — | EP | disclosed |
| CN-103917524-B | Bicyclic heterocycles | ASTELLAS PHARMA INC. (JP) | 2016-05-04 | — | — | CN | disclosed |
| US-8778871-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-15 | — | — | US | disclosed |
| US-8765909-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-01 | — | — | US | disclosed |
| US-8592379-B2 | Metastin derivative and use thereof | KYOTO UNIVERSITY (JP) | 2013-11-26 | — | — | US | disclosed |
| US-8361968-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-29 | — | — | US | disclosed |
| US-20120015868-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20110312898-A1 | PROPHYLACTIC / THERAPEUTIC AGENT FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| EP-2379053-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR CANCER | Takeda Pharmaceutical Company Limited (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20110059888-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-10 | — | — | US | disclosed |
| US-7625869-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-01 | — | — | US | disclosed |
| EP-2113513-A2 | Metastin derivatives and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2009-11-04 | — | — | EP | disclosed |
| US-20090215700-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-27 | — | — | US | disclosed |
| EP-2081955-A1 | METASTIN DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-07-29 | — | — | EP | disclosed |
| US-20080312155-A1 | Metastin Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| WO-2008050897-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-02 | — | — | WO | disclosed |
| EP-1758932-A2 | METASTIN DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-03-07 | — | — | EP | disclosed |
| US-20060241051-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-26 | — | — | US | disclosed |
| WO-2006001499-A2 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | WO | disclosed |
| EP-1577323-A1 | METASTIN DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015868-A1 | Metastin derivatives and use thereof | MET, HGFAC, HGF | MAPK1 2775/4885HTR6 3904/4885DHPS 4292/4885 |
| US-20090215700-A1 | Metastin derivatives and use thereof | SHBG, GNRHR, INHA | MAPK1 3059/4885HTR6 3976/4885DHPS 4460/4885 |
| US-20080312155-A1 | Metastin Derivatives and Use Thereof | GNRHR, SHBG, MEN1 | MAPK1 2420/4885HTR6 3884/4885DHPS 4317/4885 |
| US-20110312898-A1 | PROPHYLACTIC / THERAPEUTIC AGENT FOR CANCER | KLK3, SHBG, SERPINA3 | MAPK1 2623/4885HTR6 3853/4885DHPS 2243/4885 |
| US-20110059888-A1 | METASTIN DERIVATIVES AND USE THEREOF | SHBG, GNRHR, INHA | MAPK1 3059/4885HTR6 3976/4885DHPS 4460/4885 |
| US-20060241051-A1 | Metastin derivatives and use thereof | MET, HGFAC, HGF | MAPK1 2775/4885HTR6 3904/4885DHPS 4292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.